| Matthew Burdett, | |
|
3614 Twin Creek Dr, Bellevue, NE 68123-4065 | |
| (402) 292-3580 | |
| (402) 292-2419 |
| Full Name | Matthew Burdett |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 3614 Twin Creek Dr, Bellevue, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710394135 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 12667 (Nebraska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Matthew Burdett, 3614 Twin Creek Dr, Bellevue, NE 68123-4065 Ph: (402) 292-3580 | Matthew Burdett, 3614 Twin Creek Dr, Bellevue, NE 68123-4065 Ph: (402) 292-3580 |
News Archive
Biovail Corporation today provided an update on its Phase III program with pimavanserin for Parkinson's disease psychosis (PDP), which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top-line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program.
Today, the European Congress on Osteoporosis and Osteoarthritis opened in Valencia, Spain with some 4000 international participants. The Congress is the major annual European meeting in the bone field and attracts clinicians, specialists and bone experts from around the world. ECCEO11-IOF continues until March 26th at Valencia's Palacio de Congresos.
Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.
Researchers at the Tulane University School of Medicine, in New Orleans, LA, have demonstrated that thymoquinone a major component of black seed oil (Nigella sativa) can suppress the growth of several aggressive prostate cancer cell lines, in vitro. Although previous studies have shown the anti-proliferative effects of TQ in different types of cancers, the molecular mechanism of this effect of TQ had not been delineated.
› Verified 6 days ago
Dr. Ariel Alejandro Ruiz-burkett, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1701 Galvin Rd S, Bellevue, NE 68005 Phone: 402-292-2685 | |
Gail Boehne, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1701 Galvin Rd S, Bellevue, NE 68005 Phone: 402-292-2685 | |
Dr. Tamela L Mccreadie, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3604 Summit Plaza Dr, Bellevue, NE 68123 Phone: 402-595-1156 Fax: 402-595-1029 | |
Mr. Alan J Langpaul, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1802 Galvin Rd S, Bellevue, NE 68005 Phone: 402-291-8400 Fax: 402-291-0352 | |
Kimberly Ho, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1701 Galvin Rd S, Bellevue, NE 68005 Phone: 402-292-2685 | |
Wendy Serrano, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3614 Twin Creek Dr, Bellevue, NE 68123 Phone: 402-292-3580 | |
Ms. Angela M Matney, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Hwy 370 & Galvin Road, Bellevue, NE 68005 Phone: 402-291-8400 Fax: 402-291-0352 |